Infliximab in the treatment of pediatric Crohn's disease

Tamara L. Feldman, Joel R. Rosh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Infliximab, a murine monoclonal antibody directed against TNF-α, has been approved for the induction and maintenance of remission in moderate-to-severe pediatric Crohn's disease that is unresponsive to conventional therapy. Infliximab is administered intravenously and can be infused over 2-3 h. The recommended induction dosing schedule consists of a series of three 5 mg/kg doses of infliximab delivered at weeks 0, 2 and 6. Regularly scheduled maintenance therapy is recommended to be given every 8 weeks. While initially it was believed that the administration of concomitant immunomodulators would significantly enhance the clinical efficacy of infliximab, recent data and safety concerns have called the benefit of such a strategy into question. Currently, clinical research on the use of infliximab in pediatric Crohn's disease has focused on the unmet need of being able to identify which patients could benefit most from infliximab therapy.

Original languageEnglish (US)
Pages (from-to)15-22
Number of pages8
JournalTherapy
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Therapeutics
Remission Induction
Immunologic Factors
Pediatric Crohn's disease
Infliximab
Appointments and Schedules
Monoclonal Antibodies
Maintenance
Safety
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Feldman, Tamara L. ; Rosh, Joel R. / Infliximab in the treatment of pediatric Crohn's disease. In: Therapy. 2009 ; Vol. 6, No. 1. pp. 15-22.
@article{f1c56a84169349beb4d05ee7f541278e,
title = "Infliximab in the treatment of pediatric Crohn's disease",
abstract = "Infliximab, a murine monoclonal antibody directed against TNF-α, has been approved for the induction and maintenance of remission in moderate-to-severe pediatric Crohn's disease that is unresponsive to conventional therapy. Infliximab is administered intravenously and can be infused over 2-3 h. The recommended induction dosing schedule consists of a series of three 5 mg/kg doses of infliximab delivered at weeks 0, 2 and 6. Regularly scheduled maintenance therapy is recommended to be given every 8 weeks. While initially it was believed that the administration of concomitant immunomodulators would significantly enhance the clinical efficacy of infliximab, recent data and safety concerns have called the benefit of such a strategy into question. Currently, clinical research on the use of infliximab in pediatric Crohn's disease has focused on the unmet need of being able to identify which patients could benefit most from infliximab therapy.",
author = "Feldman, {Tamara L.} and Rosh, {Joel R.}",
year = "2009",
month = "1",
day = "1",
doi = "10.2217/14750708.6.1.15",
language = "English (US)",
volume = "6",
pages = "15--22",
journal = "Therapy",
issn = "2044-9038",
publisher = "Future Medicine Ltd.",
number = "1",

}

Infliximab in the treatment of pediatric Crohn's disease. / Feldman, Tamara L.; Rosh, Joel R.

In: Therapy, Vol. 6, No. 1, 01.01.2009, p. 15-22.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Infliximab in the treatment of pediatric Crohn's disease

AU - Feldman, Tamara L.

AU - Rosh, Joel R.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Infliximab, a murine monoclonal antibody directed against TNF-α, has been approved for the induction and maintenance of remission in moderate-to-severe pediatric Crohn's disease that is unresponsive to conventional therapy. Infliximab is administered intravenously and can be infused over 2-3 h. The recommended induction dosing schedule consists of a series of three 5 mg/kg doses of infliximab delivered at weeks 0, 2 and 6. Regularly scheduled maintenance therapy is recommended to be given every 8 weeks. While initially it was believed that the administration of concomitant immunomodulators would significantly enhance the clinical efficacy of infliximab, recent data and safety concerns have called the benefit of such a strategy into question. Currently, clinical research on the use of infliximab in pediatric Crohn's disease has focused on the unmet need of being able to identify which patients could benefit most from infliximab therapy.

AB - Infliximab, a murine monoclonal antibody directed against TNF-α, has been approved for the induction and maintenance of remission in moderate-to-severe pediatric Crohn's disease that is unresponsive to conventional therapy. Infliximab is administered intravenously and can be infused over 2-3 h. The recommended induction dosing schedule consists of a series of three 5 mg/kg doses of infliximab delivered at weeks 0, 2 and 6. Regularly scheduled maintenance therapy is recommended to be given every 8 weeks. While initially it was believed that the administration of concomitant immunomodulators would significantly enhance the clinical efficacy of infliximab, recent data and safety concerns have called the benefit of such a strategy into question. Currently, clinical research on the use of infliximab in pediatric Crohn's disease has focused on the unmet need of being able to identify which patients could benefit most from infliximab therapy.

UR - http://www.scopus.com/inward/record.url?scp=69849109060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69849109060&partnerID=8YFLogxK

U2 - 10.2217/14750708.6.1.15

DO - 10.2217/14750708.6.1.15

M3 - Article

AN - SCOPUS:69849109060

VL - 6

SP - 15

EP - 22

JO - Therapy

JF - Therapy

SN - 2044-9038

IS - 1

ER -